Email updates

Keep up to date with the latest news and content from BMC Urology and BioMed Central.

Open Access Highly Accessed Commentary

Commentary on: “Focal cryosurgical ablation of the prostate: A single institute’s perspective”

Adam R Metwalli* and Peter A Pinto

Author Affiliations

Urologic Oncology Branch, National Cancer Institute, NIH, Building 10, Room 2W-5940, 10 Center Drive, MSC 1210, Bethesda, MD 2089s, USA

For all author emails, please log on.

BMC Urology 2013, 13:39  doi:10.1186/1471-2490-13-39

Published: 2 August 2013

Abstract

The morbidity of whole gland treatment for prostate cancer is significant. Given the low risk of prostate cancer specific mortality for most men diagnosed with prostate cancer, alternative therapies such as sub-total or hemi-ablation of the prostate and focal ablation of prostate tumors are being investigated. The developing role of imaging for prostate tumors will dramatically change and likely improve the treatment morbidity for low risk prostate tumors. Commentary on: http://www.biomedcentral.com/1471-2490/13/2 webcite.

Keywords:
Prostate cancer; Therapy; Focal; Cryoablation; Image guided surgery